Clinical Trials Browser

Phase 3 × Has results × Bortezomib × Clear all

NCT04181827 2026-03-16

CARTITUDE-4

Phase 3 Active not recruiting

419 enrolled 10 charts

Multiple Myeloma

NCT03710603 2026-02-10

Perseus

Phase 3 Active not recruiting

709 enrolled 17 charts 1 FDA

Multiple Myeloma

NCT01208662 2026-01-22

DFCI 10-106

Phase 3 Active not recruiting

729 enrolled 29 charts

Multiple Myeloma, Neoplasms, Plasma Cell

NCT02112916 2025-12-01

Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma

Phase 3 Active not recruiting

847 enrolled 19 charts

LymphoidOther hematologic neoplasm

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT01371981 2025-11-26

Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Phase 3 Active not recruiting

1,645 enrolled 32 charts

Other hematologic neoplasmSarcoma

Leukemia, Myeloid, Acute, Sarcoma, Myeloid

NCT01241708 2025-09-17

(Mel/MelVel)

Phase 3 Completed

148 enrolled 12 charts

Multiple Myeloma

NCT02136134 2025-08-29

Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma

Phase 3 Completed

498 enrolled 15 charts

Multiple Myeloma, Plasmacytoma

NCT02195479 2025-08-22

A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma

Phase 3 Completed

706 enrolled 29 charts

Multiple Myeloma

NCT06956170 2025-06-11

DREAMM 8

Phase 3 Active not recruiting

21 enrolled 9 charts

Multiple Myeloma

NCT06868667 2025-05-09

DREAMM 7

Phase 3 Active not recruiting

24 enrolled 10 charts

Multiple Myeloma

NCT02541383 2025-04-13

Cassiopeia

Phase 3 Completed

1,085 enrolled 22 charts 1 FDA

Multiple Myeloma

NCT04484623 2025-03-18

DREAMM 8

Phase 3 Active not recruiting

302 enrolled 10 charts

Multiple Myeloma

NCT01539083 2025-02-04

VCAT

Phase 3 Completed

256 enrolled 13 charts

Multiple Myeloma

NCT04246047 2024-10-24

DREAMM 7

Phase 3 Active not recruiting

494 enrolled 10 charts 1 FDA

Multiple Myeloma

NCT03110562 2024-08-21

BOSTON

Phase 3 Completed

402 enrolled 22 charts 2 FDA

Multiple Myeloma, Recurrence

NCT02755597 2023-08-22

Bellini

Phase 3 Completed

291 enrolled 24 charts

Multiple Myeloma

NCT01078454 2022-02-01

Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis

Phase 3 Completed

11 enrolled 6 charts

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

NCT01109004 2021-12-09

BMT CTN 0702

Phase 3 Completed

758 enrolled 21 charts

Hematologic Diseases, Multiple Myeloma, Disease Progression

NCT00256776 2021-10-18

MMVAR - Velcade: Study of Velcade for the Treatment of Myeloma Patients After Autologous Transplantation

Phase 3 Terminated

269 enrolled 9 charts

Multiple Myeloma, Recurrence

NCT00773747 2021-04-30

Study of Vorinostat (MK-0683) or Placebo, in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-088 AMN)

Phase 3 Completed

637 enrolled 15 charts

LymphoidPlasma cell

Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, Hemorrhagic Disorders, Immune System Diseases, Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Vascular Diseases, Hemostatic Disorders, Neoplasms, Plasma Cell

NCT01023308 2020-03-17

PANORAMA-1

Phase 3 Completed

767 enrolled 17 charts

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT01146834 2019-12-27

Trial of Three Stem Cell Mobilization Regimens for Multiple Myeloma

Phase 3 Completed

47 enrolled 12 charts

Multiple Myeloma

NCT01818752 2019-08-26

CLARION

Phase 3 Completed

955 enrolled 20 charts

Multiple Myeloma

NCT02489500 2018-09-10

VelRand

Phase 3 Terminated

3 enrolled 11 charts

Immunoglobulin Light-chain Amyloidosis

NCT00722137 2018-07-12

Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma

Phase 3 Completed

487 enrolled 20 charts

Lymphoma, Mantle-Cell

NCT00574080 2017-11-20

UARK 2006-15: A Study of Tandem Transplants With or Without Bortezomib and Thalidomide

Phase 3 Terminated

20 enrolled 7 charts

Multiple Myeloma

NCT00657553 2017-11-20

2007-77

Phase 3 Terminated

10 enrolled 5 charts

Multiple Myeloma

NCT00103506 2015-10-19

Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma

Phase 3 Completed

646 enrolled 10 charts

Multiple Myeloma

NCT00522392 2015-06-26

Bortezomib and Dexamethasone With or Without Lenalidomide in Treating Patients With Multiple Myeloma Previously Treated With Dexamethasone

Phase 3 Terminated

48 enrolled 9 charts

Multiple Myeloma

NCT00813150 2014-08-15

Study of Bortezomib and Dexamethasone With or Without Cyclophosphamide in Patients With Relapsed or Not Controllable Multiple Myeloma

Phase 3 Completed

96 enrolled 12 charts

Multiple Myeloma, Neoplasms

NCT00507416 2014-05-01

UPFRONT

Phase 3 Completed

502 enrolled 17 charts

Multiple Myeloma

NCT01801436 2013-05-16

A Post-Approval Pharmacokinetic Study of Bortezomib in Participants With Multiple Myeloma

Phase 3 Completed

14 enrolled 34 charts

Multiple Myeloma

NCT00573391 2011-08-12

Study of Multiple Myeloma Patients Relapsing or Progressing After Autologous Transplantation on Total Therapy 2

Phase 3 Terminated

5 enrolled 6 charts

Multiple Myeloma